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Summary
To re-examine the correlation between mtDNA variability and
longevity, we examined mtDNAs from samples obtained from
over 2200 ultranonagenarians (and an equal number of controls)
collected within the framework of the GEHA EU project. The
samples were categorized by high-resolution classification, while
about 1300 mtDNA molecules (650 ultranonagenarians and an
equal number of controls) were completely sequenced.
Sequences, unlike standard haplogroup analysis, made possible
to evaluate for the first time the cumulative effects of specific,
concomitant mtDNA mutations, including those that per se have
a low, or very low, impact. In particular, the analysis of the
mutations occurring in different OXPHOS complex showed a
complex scenario with a different mutation burden in 90+
subjects with respect to controls. These findings suggested that
mutations in subunits of the OXPHOS complex I had a beneficial
effect on longevity, while the simultaneous presence of muta-
tions in complex I and III (which also occurs in J subhaplogroups
involved in LHON) and in complex I and V seemed to be
detrimental, likely explaining previous contradictory results. On
the whole, our study, which goes beyond haplogroup analysis,
suggests that mitochondrial DNA variation does affect human
longevity, but its effect is heavily influenced by the interaction
between mutations concomitantly occurring on different mtDNA
genes.
Key words: genetics of longevity; longevity; mitochondrial
DNA; mtDNA sequencing; oxidative phosphorylation.
Introduction
Research on mitochondrial biology has underlined the central role
played by the mitochondrion in a number of complex traits, including
aging and metabolic and degenerative diseases. Mitochondria, due to
their central position between energy uptake and energy production,
are involved in a number of cellular processes such as heat production,
apoptosis regulation, and cellular differentiation. In addition, mito-
chondria are responsible for the production and the regulation of the
most important by-product of the cellular metabolism, reactive oxygen
species (ROS), which are widely considered to be one of the main
causes of aging (for a review see Passarino et al., 2010; Wallace,
2010). Most of the proteins determining the biology of mitochondria
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are encoded by the nuclear genome, but some important subunits of
the oxidative phosphorilation (OXPHOS) are encoded by the mitochon-
drial DNA (mtDNA). Thus, many studies have addressed the effects of
nuclear and mitochondrial DNA mutations (and of the interaction
between the two genomes) on mitochondrial functioning and its effect
on aging in model organisms and in humans (for a review, see
Lagouge & Larsson, 2013; Bratic & Larsson, 2013; Greaves & Turnbull,
2009). In particular, many studies on humans have addressed the role
played by the common variability of mitochondrial DNA in modulating
the processes influenced by mitochondrial activity, and their effects on
degenerative diseases and aging (Brown et al., 1997; Ivanova &
Lepage, 1998; De Benedictis et al., 1999; Ruiz-Pesini et al., 2000; Ross
et al., 2001; Rose et al., 2002; Niemi et al., 2003; van der Walt et al.,
2003; Wallace, 2005; Montiel-Sosa et al., 2006; Santoro et al., 2006).
These studies have been carried out mainly by taking advantage of the
haplogroup classification of mtDNA molecules. Using this approach, we
previously reported a beneficial effect of haplogroup J, present across
Europe and the Near East, on longevity, being more frequent in
centenarians than in ethnically matched younger controls in northern
Italy (De Benedictis et al., 1999), Ireland (Ross et al., 2001), and
Finland (Niemi et al., 2003). Intriguingly, haplogroup J was also
reported to be strongly associated with LHON (Leber’s hereditary optic
neuropathy), increasing the penetrance of specific mutations that are
significantly less harmful when occurring in mtDNA molecules of
different haplogroups (Brown et al., 1997; Torroni et al., 1997; Man
et al., 2004). Similarly, the Asian haplogroup D (characterized by
mutations affecting complex I, such as haplogroup J) has been found
to be overrepresented in Japanese centenarians (Tanaka et al., 1998,
2000). Accordingly, it was proposed that the mutations defining the
J haplogroup (falling in the protein subunits of OXPHOS complex I)
decrease OXPHOS activity, putting the cell in a vulnerable situation
where a further mutation (such as in LHON) would be more likely to be
harmful. However, if the nuclear response stimulated by higher ROS
production is adequate, the low OXPHOS activity may become
advantageous and lead to lower ROS levels, resulting in more healthy
aging (Rose et al., 2001). Consistent with this hypothesis, cells with
mtDNA molecules belonging to haplogroup J were recently found to
produce less ATP and less ROS than cells with different mtDNA
molecules (Bellizzi et al., 2012). However, some studies have failed to
find any association between mtDNA and longevity (Dato et al., 2004;
Pinos et al., 2012; Collerton et al., 2013), suggesting that the possible
effect of mtDNA on longevity might be population specific, but also
that such an effect might be minimal, and require a very large number
of samples to reach statistical significance. In addition, it is possible
that the analysis of mitochondrial DNA haplogroups may not be a
suitable approach to uncover the effects of mtDNA given that different
sporadic mutations suggested to be important for human longevity
(see Beekman et al., 2013) fall along mtDNA molecules but are not
associated with any of the haplogroups.
Here, we present the results of a very large study, where over 2200
subjects older than 90 years, recruited within the framework of the
Genetics of Healthy Ageing (GEHA) EU project (Skytthe et al., 2011) and
coming from most of the European populations, were compared with a
similar number of younger controls matched for sex and geographical
origins. In this study, we also availed of the complete sequencing of a
subgroup of GEHA samples [650 ultra nonagenarians (90+) and a
comparable number of controls, coming from Denmark, Finland,
southern Italy and Greece], to determine whether recurrent or sporadic
mutations accumulated in specific genes not detected by haplogroup
analysis, may influence longevity.
Results
Haplogroup analysis
The frequencies of mtDNA haplogroups in 90+ and controls are
summarized in Table 1 and, separately for men and women, in Table
S1. We observed that in females, the haplogroups H2 and T2 are more
frequent in the 90+ group than in controls (P = 0.002 and 0.02,
respectively). On the other hand, among male controls, the frequency of
haplogroups H1 and J2 was higher than in the 90+ group (P = 0.023 and
0.004, respectively). No association was detectable when multiple test
corrections were used.
Sequence analysis
The mtDNA sequences have been deposited in GenBank, with accession
numbers JX152783 – JX154074.
To analyze the mtDNA sequences, we first compared all complete
sequences with the reference sequence (rCRS). A summary of all
identified mutations is shown in Table S2. The analysis of single
mutations did not highlight any specific mutation that could consistently
account for an advantage in longevity.
Thus, we analyzed the possibility that nonsynonymous mutations may
alter specific genes and affect the chances of attaining extreme
longevity. We analyzed mtDNA sequences of ultranonagenarians and
Table 1 Distribution of mtDNA haplogroups in the Genetics of Healthy Ageing
(GEHA) samples
Subhaplogroups
Controls
(n = 2153)
90+
(n = 2086)
P-valueN % N %
HV* 1042 48.4 1052 50.43 0.187
HV0* 68 3.16 83 3.98 0.159
H* 924 42.92 927 44.44 0.322
H1 325 15.1 292 14 0.317
H2 23 1.07 42 2.01 0.013
H3 85 3.95 71 3.4 0.370
H5 63 2.93 68 3.26 0.536
H6 47 2.18 52 2.49 0.542
I 44 2.04 46 2.21 0.750
J 210 9.75 183 8.5 0.289
J1 153 7.11 144 6.9 0.810
J2 57 2.65 39 1.87 0.099
K 161 7.48 137 3.98 0.254
K1 140 6.5 117 5.61 0.247
T 211 9.8 223 10.69 0.362
T1 53 2.46 43 2.06 0.410
T2 152 7.06 174 8.34 0.120
U 313 14.54 272 13.04 0.167
U2 39 1.81 38 1.82 1.000
U4 48 2.23 34 1.63 0.181
U5a 109 5.06 90 4.31 0.276
U5b 56 2.6 51 2.44 0.770
W 39 1.81 51 2.44 0.166
X 41 1.9 42 2.01 0.825
OTHER 92 5.53 80 5.08 0.484
*is part of the internationally used designation of these groups of haplotypes.
Haplogroups and subhaplogroups with frequencies higher than 1.5% are
reported. OTHER includes N1a, N1b, N1c, N9a, A4, D5, C1d, M1, L1b1.
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controls to find an aggregate mtDNA variation associated with longevity.
To avoid false-positive results as much as possible, the analysis of mtDNA
sequences was carried out using a gene-based kernel approach (Wu
et al., 2011), adjusted for genetic ancestry by means of principal
component analysis according to Biffi et al. (2010) and corrected for
multiple testing (number of ‘genes’ analyzed). In our case, we considered
a ‘gene’ as all the subunits encoded by mtDNA and belonging to a single
complex of OXPHOS (ND 1-6 and ND4L are in complex I, Cyt b in
complex III, COI-III in complex IV, ATPase 6 and 8 in complex V). Table 2
reports the results of the gene-based analysis, while Fig. S1 shows the
results of the underlying principal component analysis. Table 2 clearly
shows that nonsynonymous mutations falling within Complex I, III and V
are associated with longevity in our sample. By contrast, there was no
correlation between synonymous mutations falling in different subunits
of OXPHOS encoded by mitochondrial DNA. No significant correlation
was observed for either rRNA genes or tRNA genes.
To better understand the results and, in particular, to determine
whether mutations falling in different complexes have a positive or
negative effect, we compared 90+ and controls in different populations
for nonsynonymous mutations in genes belonging to the mitochondrial
complex that was significantly associated with longevity upon the gene-
based sequence analysis above (Fig. 1). When we considered the
subunits of complex I, all three populations showed a difference
between 90+ and controls. However, the frequency of nonsynonymous
mutations was higher in controls than in the 90+ belonging to Danish
and southern European populations (respectively, P = 0.03 in Denmark
and P << 0.001 in South Europe), while in the Finnish population, we
observed the opposite trend (P = 0.02).
Table 2 Results of sequence analysis according to sequence kernel association test (SKAT) to find aggregate gene-based associations for human longevity using the 1840
mtDNA SNPs
Number of SNPs P-value
Nonsynonymous mutations Synonymous mutations
Number of SNPs P-Value Number of SNPs P-value
Complex I 712 200 0.02648710 512 0.39526309
Complex III 136 54 0.03876515 82 0.17760404
Complex IV 321* 85 0.51612941 235 0.36290044
Complex V 134 74 0.00057112 60 0.14215469
rRNA 154 0.43332840
tRNA 100 0.26393589
Control region 267 0.10580026
P-values were obtained, by bootstrap analysis (10 000 bootstrap), using the SKAT algorithm after adjusting for the first four principal components.
*One position is noncoding (position 8269, in COII).
Fig. 1 Nonsynonymous mutation
frequencies in 90+ and controls in mtDNA
genes of OXPHOS complexes I, III and V,
which showed a significant association with
longevity after sequence analysis for pooled
associations (Table 2). * indicates statistical
significant differences between 90+ and
controls. Frequency (y-axis) indicates the
average number of mutation per subject
every 100 bp of the relevant mtDNA
region. DK, FI, and SE stand for Denmark,
Finland, and South Europe populations,
respectively.
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For complex III and V, Danish and southern European populations
showed a higher frequency of mutations in controls than in the 90+
group (P = 0.005 in Denmark and P = 0.048 in South Europe)
(P = 0.0011 and P = 0.0023, respectively), while in the Finnish popula-
tion, the mutation frequency did not differ between the 90+ and
controls for both complexes.
Given the absolute linkage among mtDNA mutations, we investigated
whether the different results obtained in our samples (with Finns showing
a different trend with respect to other samples) could be due to a
different distribution of the simultaneous mutations in subunits of
different complexes. As most of the samples showed at least one
mutation in both complexes I and III, for each sample, we counted the
subjects where we observed two or more mutations in the subunits of
both complex I and complex III (Table 3a). Indeed, we observed that,
when controls are considered, both Danes and southern Europeans show
a higher frequency of the simultaneous presence of two mutations in
complex I and III than Finns (P = 0.04 and P = 0.006, respectively). The
same result was obtained when complex I and V were considered
(Table 3b). In both cases, the number of subjects with two or more
mutations in complex I and III or in complex I and V was higher in controls
than in ultranonagenarians (P = 0.03 and P = 0.02, respectively).
Discussion
Previous analyses on the correlation between mitochondrial DNA
variability and longevity in humans have produced interesting but
contradictory results (Passarino et al., 2010 and references therein). The
large GEHA sampling of European ultranonagenarians with sex- and
geographically matched controls, and the complete sequencing of a
great number of mtDNA molecules allowed us to shed light on this
contradictory scenario. The unprecedented number of samples collected
and analyzed makes these results very relevant in the longevity and
mtDNA fields. The results are reinforced by the specific attention to the
recruitment procedure aimed at minimizing population sampling bias
stipulated by the GEHA project (see Experimental procedures).On the
other hand, it must be acknowledged that cases and controls come from
different birth cohorts, as it happens for studies on longevity, and this
may represent a limitation.
The analysis of haplogroups showed that haplogroups H2 and T2 are
associated with longevity in females. Haplogroup J2 was also associated
with longevity in males, showing an opposite trend with respect to
previous studies (Niemi et al., 2003; Domınguez-Garrido et al., 2009). In
fact, J2 turned out to be less frequent in 90+ than in controls. Although
none of these associations held after multiple tests adjustment, it is
interesting to note that the haplogroups H2, T (including T2) and J
(including J2) are characterized by nonsynonymous mutations in subunits
of OXPHOS complex I, which, as mentioned above, has previously,
although not consistently, been suggested to be associated with
longevity.
Although the analysis of mtDNA haplogroups provided some interest-
ing data, it proved once again to be unable to fully shed light on the
correlation between mtDNA variability and longevity. The analysis of
sequencing data showed that the pooled nonsynonymous variability of
each of OXPHOS complexes I, III and V is associated with longevity.
However, complex I exhibited highermutation frequency in the 90+ group
than in controls in Finns (suggesting that mutations in these subunits may
be beneficial), but it showed more mutations in controls than in 90+ in
Danish and in southern Europeans (suggesting that mutations in the
subunits of complex I may be detrimental). On the other hand, also for
complexes III and V, Danes and southern Europeans had a similar trend
with more nonsynonymous mutations in controls than in ultranonage-
narians, while Finns showed no differences between ultranonagenarians
and controls for both complexes. The analysis of the simultaneous
presence of mutations on both complexes I and III and in both complexes I
and V suggests that the presence of mutation on complex I may be
beneficial for longevity, while the co-occurrence of mutations on both
complexes I and III or on both I and V might lower the individual’s chances
for longevity. It might be worth mentioning in this context that studies on
the molecular basis of LHON showed that the penetrance of LHON
mutations is greatly increasedby the concomitantoccurrenceofmutations
on complexes I and III defining specific J subhaplogroups, such as J1c and
J2b (Carelli et al., 2006; Achilli et al., 2012). Accordingly, this result might
explain why the J haplogroup is associated with longevity in some
populations but not in others. In populationswhere J subhaplogroupswith
additional mutations in complex III (or complex V) are more frequent, we
may expect to find no association between J and longevity, similarly to
what has been reported regarding the absence of correlation between
haplogroup J and LHON in populations where these subhaplogroups are
not present (Carelli et al., 2006). Indeed previous analyses had shown that
haplogroup J is associated with longevity in Finns but not in southern
Italians (De Benedictis et al., 1999; Niemi et al., 2003; Dato et al., 2004).
On the basis of our results, we can hypothesize thatmutations in complex I
may decrease the rate ofOXPHOS, possibly by slowing the initiation rate of
the electron transport chain, thus leading to a lower production of both
ATP and ROS, as suggested in an in vitro study by Bellizzi et al. (2012). In
contrast, the impairment of supercomplex I–III (or of complexes I andV) can
affect the activity of OXPHOS by decreasing (or, at worse, blocking) the
initiated electron transport chain, leading to higher ROSproduction and/or
hyperpolarization of the mitochondrial membrane (Wallace, 2005). This
hypothesis takes into account available data but will certainly need to be
studied in vivo using appropriate models with specific mutations. In fact,
our results are based on the different genetic burden of NS mutations in
Table 3 (a) Samples with 2 or more mutations in both complex I and III;
(b) samples with 2 or more mutations in both complex I and V
Population (n. total sample) n. sample %
(a)
Denmark controls (429) 131 30.53
inland controls (166) 32 21.91
South Europe controls (71) 28 39.43
Total controls (666) 191 28.67*
Denmark 90+ (423) 117 27.66
Finland 90+ (148) 23 15.54
South Europe 90+ (75) 22 18.66
Total 90+(646) 162 25.07*
(b)
Denmark controls (429) 55 12.82
Finland controls (166) 17 10.24
South Europe controls (71) 13 18.31
Total Controls (666) 85 12.76†
Denmark 90+ (423) 39 9.22
Finland 90+ (148) 11 7.43
South Europe 90+ (75) 7 9.33
Total 90+(646) 57 8.82†
*The co-occurrence of two or more mutations in complex I and III is more frequent
in controls than in 90+ (P = 0.03).
†The co-occurrence of two or more mutations in complex I and V is more frequent
in controls than in 90+ (P = 0.02).
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90+ participants when compared with controls, but they are limited to
explain epistatic interactions and the real effect of the mutations. Future
work will need to better characterize the molecular effects of single
mutations. Moreover, it will be important also to better analyze the
interaction between these mutations and mutations in the regulatory
region affecting mtDNA expression, as the 295C/T transition which was
showed to affect mitochondrial transcription and copy number in cybrid
models and is typical of haplogroup J (Suissa et al., 2009).
It is also worth mentioning that the availability of complete sequences
allowed us to evaluate the frequency of mutations previously reported to
be associated with degenerative diseases in 90+ and controls (Table S3).
Unexpectedly, such mutations are present in the 90+ group sometimes
at higher frequencies than in controls. For instance, the 4336T>C
mutation in the tRNAgln has been found to be more frequent in patients
with AD than in controls by a number of studies between 1993 and
2010 (Shoffner et al., 1993; Hutchin & Cortopassi, 1995; Brown et al.,
1996; Santoro et al., 2010). We found this mutation to be twice as
frequent in 90+ than in controls. Similarly, many other supposed
deleterious mutations have been found to be quite frequent in 90+.
These results support the idea that certain mtDNA-inherited mutations
could contribute to longevity or disease according to population- and
individual-specific genetic backgrounds (nuclear genome and combina-
tion of mtDNA mutations), as well as stochastic events (Rose et al.,
2001; Moilanen et al., 2003; Wallace, 2010).
In conclusion, we postulate that particular rare mtDNA mutations,
present only in specific populations, might be beneficial (or detrimental)
for longevity and may explain part of the genetic component of longevity
in that population, similarly to what has been suggested for private
nuclear DNA polymorphisms (Beekman et al., 2013). On the whole, our
study has allowed the reappraisal of the correlation between mtDNA
variability and longevity. We show that complete mtDNA sequencing
and analysis of its whole variability can highlight correlations between
mtDNA variability and a specific phenotype, such as longevity which
escapes standard haplogroup analysis. In fact, complete sequence
analysis allows the appreciation of the effects of rare or repeated
mutations unaccounted for in haplogroup analysis (Rollins et al., 2009).
In addition, we have better highlighted the beneficial effects on
longevity of mutations in the subunits of OXPHOS complex I and the
detrimental effects of mutations in subunits of complex III or V (also in
presence of mutations in complex I). It is important to underline that the
very small effect of these mutations on longevity requires a very large
sample size to be significantly highlighted.
Finally, we have also shown that mtDNA mutations, previously found
to be associated with a number of degenerative disorders, are present in
ultranonagenarians and in some cases even at higher frequencies than in
controls. Again, this suggests that mtDNA mutations can be either
positive or negative according to other factors, most likely including
environmental factors as well as other mitochondrial and nuclear
genomic background.
Experimental procedures
Sampling
Samples were collected within the framework of the GEHA research
project (2004–2010) in 11 European Countries. Each institution provid-
ing blood samples received the approval from its own ethical committee,
and all the recruited subjects provided written informed consent for the
use of their phenotypic and genetic data in studies on human aging
(Skytthe et al., 2011).
Within GEHA, families with two or more siblings 90 years old or older
were identified with different strategies depending on the available
information on the population. Once identified, individuals were
contacted and an appointment was made to visit the individual in his
or her usual place of residence. During the visit, a structured interview
was conducted based on a standardized questionnaire, and blood
samples consisting of three 7.5 mL EDTA tubes of blood were collected
from each participant. For this study, we used only the older brother of
each sibship.
The following inclusion criteria were applied to the recruitment of
younger controls: (i) the participant should be between 50 and 75 years
of age; (ii) he or she should be genetically unrelated to the old siblings to
whom he/she was assigned as control; (iii) he or she should be of the
same ethnicity and geographical background as the old siblings; (iv)
whenever possible, he or she should be of the same gender as the oldest
sibling in the sib pair or group. In cases where it was possible to contact
the spouse of a child of an old sibling, he/she was asked to participate.
Alternatively, control volunteers were recruited from the same geo-
graphical area as the ultranonagenarians (further details on the sampling
can be found on Skytthe et al., 2011).
DNA was recovered from fresh blood by automated and standardized
protocol to guarantee quality and concentration uniformity among
samples. The GEHA Partner in charge of the DNA extraction (KTL –
Helsinki, Finland) provided 4 lg of genomic DNA for mtDNA variability
analysis.
A total of 4239 samples were available for mitochondrial haplogroup
classification and for exploring the possible association between mtDNA-
inherited sequence variation and longevity. Samples were distributed
among ultranonagenarians (90+) and younger controls as reported in
Table S4 and had the features reported in Table S5 (Supporting
Information).
mtDNA Sequence Variation Screening
From the 4239 samples available, 1292 (646 ultranonagenarians and
646 controls) were selected for complete sequencing to analyze the
differences between northern and southern European populations in the
whole DNA molecule. For the remaining 2947 samples (1449 ultrano-
nagenarians and 1498 controls), the mtDNA subhaplogroup was
determined to verify possible haplogroup association with longevity
and to compare haplogroup distribution among different European
countries.
Complete sequencing was performed using two different protocols
previously compared for the reliability of results by parallel testing of
samples. A total of 125 sequences (109 Calabrians and 16 Greeks) were
obtained using the MitoALL Resequencing kit (Applera, Foster City, CA,
USA) introducing four alternative primer pairs to improve the amplifi-
cation rate (Table S6). Each amplification step was followed by
purification with EXOSAPit (U.S. Biochemical, Cleveland, Ohio). The
sequencing reaction was conducted using the BigDye Kit, version 3.1
(Applera), and M13 universal primers (forward and reverse), followed by
purification of the sequences by ethanol precipitation. Electrophero-
grams were analyzed with SEQSCAPE, version 2.5 software (Applera), that
allows the assembly of all 46 fragments belonging to the sample and to
align and compare the obtained consensus sequence with the revised
Cambridge Reference Sequence (rCRS, NCBI: NC_012920.1 gi:251831
106) (Andrews et al., 1999). Two independent operators manually
verified sequences for phantom mutations by reads of both strands. The
remaining samples were sequenced in Beijing Genomics Institute (BGI) as
previously described (Wang et al., 2008).
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The definition of the mtDNA subhaplogroups in the remaining 2947
samples was conducted by resequencing the D-loop region from
nucleotide position (np) 16024 to np 576 followed by RFLP analysis in
specific coding region traits as previously described (Torroni et al., 1996).
For the haplogroup and subhaplogroup assignment, we followed the
Phylotree nomenclature (www.phylotree.org) (van Oven & Kayser,
2009). Considering the number of samples to classify, we developed a
custom tree search algorithm that, coupled with a highly-efficient SNP
discovery pipeline, is able to define the haplogroup that better matches
the sample mutational motifs, starting from the raw sequence in FastA
format (Vianello et al., 2013).
Statistical analysis
R statistical software was used for all statistical analyses. mtDNA
subhaplogroups and relevant frequencies were stratified by gender
and were compared between 90+ subjects and their ethnically matched
controls using the chi-squared test with Pearson correction or Fisher’s
exact test. The comparison of frequencies in 90+ and younger controls of
each mtDNA subhaplogroup was computed by applying Pearson’s chi-
squared test with Yates’ continuity correction. Tests for statistical
significance were two-sided with a = 0.05.
Principal component analysis with mitochondrial SNPs passing quality
control (MAF > 0.01), was used to control for hidden population
substructure in the following association analyses (Biffi et al., 2010). This
method has been shown to outperform haplogroup-stratified or
haplogroup-adjusted association analyses with no loss in power for the
detection of true associations. Principal component analysis was
performed using the SNPRelate R package (Zheng et al., 2012) using
only individuals of European ancestry.
Rare-Variant association testing for sequencing data was carried out to
detect rare mtDNA variants involved in human longevity. For this purpose,
the SKAT algorithmwas used: a supervised and flexible regressionmethod
to test for association between rare variants in a gene or genetic region
with a continuous/dichotomous trait. This algorithm was implemented in
the SKAT package of R. Compared with other gene-based approach,
SKAT is able to deal with variants that have different direction and
magnitude of effects, allows for covariate adjustment, and also avoids
arbitrary selection of threshold in burden test (Wu et al., 2011). Gene-
based analysis was adjusted for the first four PCs derived from the
principal component analysis previously described. To compute the SKAT
P-values, we used a resampling procedure based on 10 000 bootstraps.
The function used tomeasures the genetic similarity between two random
subjects i and i’ in the analyzed region via the P selected markers was the
weighted linear kernel function. As suggested by Wu et al. (2011), the
diagonal weight matrix was chosen using the beta distribution density
function with parameters a1 = 1 and a2 = 25 evaluated at the sample
minor-allele frequency or MAF (default option of SKAT package of R).
Acknowledgments
The study was supported by the GEHA Project.
Funding
This project was funded through Priority 1 (Life Sciences, Genomics and
Biotechnology for Health) of European Union’s FP6, Project Number
LSHM-CT-2004-503270. The research also received funding from the
European Union’s Seventh Framework Programme (FP7/2007-2011)
under Grant Agreement No 259679.
Author contribution
N. Raule, F. Sevini, S. Lin, K. Majamaa, M. Perola, L. Bolund, H. Yang,
G. Passarino and C. Franceschi designed and coordinated the study.
T. E. Johnson collaborated in defining the design and assisted in the
coordination of the study. N. Raule, F. Sevini, S. Li, A. Barbieri, L. Lomartire,
carried out laboratory analyses. F. Tallaro, D. Vianello, G. Rose, A.
Montesanto, J. Moilanen carried out bioinformatic and statistic analyses.
V. Bezrukov, H. Blanche, A.Hervonen, K. Christensen, L. Deiana, E. Gonos,
T.B.L. Kirkwood,P. Kristensen,A. Leon, P.G. Pelicci,M. Poulain, I.M. Rea, J.
Remacle, J.M. Robine, S. Schreiber, E. Sikora, P.E. Slagboom, L. Spazza-
fumo, M.A. Stazi, O. Toussaint, J.W. Vaupel, M. Perola, G. Passarino, C.
Franceschi provided samples and opportunity to carry out the analysis. N.
Raule, F. Sevini, G. Passarino and C. Franceschi wrote the Manuscript.
Conflict of interest
The authors declare no conflict of interest.
References
Achilli A, Iommarini L, Olivieri A, Pala M, Hooshiar Kashani B, Reynier P, La Morgia
C, Valentino ML, Liguori R, Pizza F, Barboni P, Sadun F, De Negri AM, Zeviani M,
Dollfus H, Moulignier A, Ducos G, Orssaud C, Bonneau D, Procaccio V,
Leo-Kottler B, Fauser S, Wissinger B, Amati-Bonneau P, Torroni A, Carelli V
(2012) Rare primary mitochondrial DNA mutations and probable synergistic
variants in Leber’s hereditary optic neuropathy. PLoS ONE 7, e42242.
Andrews RM, Kubacka I, Chinnery PF, Lightowlers RN, Turnbull DM, Howell N
(1999) Reanalysis and revision of the Cambridge reference sequence for human
mitochondrial DNA. Nat. Genet. 23, 147.
Beekman M, Blanche H, Perola M, Hervonen A, Bezrukov V, Sikora E, Flachsbart F,
Christiansen L, De Craen AJ, Kirkwood TB, Rea IM, PoulainM, Robine JM, Valensin
S, Stazi MA, Passarino G, Deiana L, Gonos ES, Paternoster L, Sørensen TI, Tan Q,
Helmer Q, van den Akker EB, Deelen J,Martella F, Cordell HJ, Ayers KL, Vaupel JW,
T€ornwall O, Johnson TE, Schreiber S, Lathrop M, Skytthe A, Westendorp RG,
Christensen K, Gampe J, Nebel A, Houwing-Duistermaat JJ, Slagboom PE,
Franceschi C; GEHA consortium (2013) Genome-wide linkage analysis for human
longevity: Genetics of Healthy Aging Study. Aging Cell 12, 184–193.
Bellizzi D, D’Aquila P, Giordano M, Montesanto A, Passarino G (2012) Global DNA
methylation levels are modulated by mitochondrial DNA variants. Epigenomics 4,
17–27.
Biffi A, Anderson CD, Nalls MA, Rahman R, Sonni A, Cortellini L, Rost NS, Matarin
M, Hernandez DG, Plourde A, de Bakker PI, Ross OA, Greenberg SM, Furie KL,
Meschia JF, Singleton AB, Saxena R, Rosand J (2010) Principal-component
analysis for assessment of population stratification in mitochondrial medical
genetics. Am. J. Hum. Genet. 86, 904–917.
Bratic A, Larsson NG (2013) The role of mitochondria in aging. J. Clin. Invest. 123,
951–957.
Brown MD, Shoffner JM, Kim YL, Jun AS, Graham BH, Cabell MF, Gurley DS,
Wallace DC (1996) Mitochondrial DNA sequence analysis of four Alzheimer’s
and Parkinson’s disease patients. Am. J. Med. Genet. 61, 283–289.
Brown MD, Sun F, Wallace DC (1997) Clustering of Caucasian Leber hereditary
optic neuropathy patients containing the 11778 or 14484 mutations on an
mtDNA lineage. Am. J. Hum. Genet. 60, 381–387.
Carelli V, Achilli A, Valentino ML, Rengo C, Semino O, Pala M, Olivieri A, Mattiazzi
M, Pallotti F, Carrara F, Zeviani M, Leuzzi V, Carducci C, Valle G, Simionati B,
Mendieta L, Salomao S, Belfort R Jr, Sadun AA, Torroni A (2006) Haplogroup
effects and recombination of mitochondrial DNA: novel clues from the analysis of
Leber hereditary optic neuropathy pedigrees. Am. J. Hum. Genet. 78, 564–774.
Collerton J, Ashok D, Martin-Ruiz C, Pyle A, Hudson G, Yadegarfar M, Davies K,
Jagger C, von Zglinicki T, Kirkwood TB, Chinnery PF (2013) Frailty and mortality
are not influenced by mitochondrial DNA haplotypes in the very old. Neurobiol.
Aging 34, 2889.
Dato S, Passarino G, Rose G, Altomare K, Bellizzi D, Mari V, Feraco E, Franceschi C,
De Benedictis G (2004) Association of the mitochondrial DNA haplogroup J with
longevity is population specific. Eur. J. Hum. Genet. 12, 1080–1082.
De Benedictis G, Rose G, Carrieri G, De Luca M, Falcone E, Passarino G, Bonafe M,
Monti D, Baggio G, Bertolini S, Mari D, Mattace R, Franceschi C (1999)
mtDNA variability and longevity, N. Raule et al.406
ª 2013 The Authors. Aging Cell published by the Anatomical Society and John Wiley & Sons Ltd.
Mitochondrial DNA inherited variants are associated with successful aging and
longevity in humans. FASEB J. 13, 1532–1536.
Domınguez-Garrido E, Martınez-Redondo D, Martın-Ruiz C, Gomez-Duran A,
Ruiz-Pesini E, Madero P, Tamparillas M, Montoya J, von Zglinicki T, Dıez-Sanchez
C, Lopez-Perez MJ (2009) Association of mitochondrial haplogroup J and
mtDNA oxidative damage in two different North Spain elderly populations.
Biogerontology 10, 435–442.
Greaves LC, Turnbull DM (2009) Mitochondrial DNA mutations and ageing.
Biochim. Biophys. Acta 1790, 1015–1020.
Hutchin T, Cortopassi G (1995) A mitochondrial DNA clone is associated with
increased risk for Alzheimer disease. Proc. Natl Acad. Sci. USA 92, 6892–6895.
Ivanova R, Lepage V (1998) Mitochondrial genotype associated with French
Caucasian centenarians. Gerontology 44, 349.
Lagouge M, Larsson NG (2013) The role of mitochondrial DNA mutations and free
radicals in disease and ageing. J. Intern. Med. 273, 529–543.
Man PY, Howell N, Mackey DA, Nørby S, Rosenberg T, Turnbull DM, Chinnery PF
(2004) Mitochondrial DNA haplogroup distribution within Leber hereditary optic
neuropathy pedigrees. J. Med. Genet. 41, e41.
Moilanen JS, Finnila S, Majamaa K (2003) Lineage-specific selection in human
mtDNA: lack of polymorphisms in a segment of MTND5 gene in haplogroup.
J. Mol. Biol. Evol. 20, 2132–2142.
Montiel-Sosa F, Ruiz-Pesini E, Enrıquez JA, Marcuello A, Dıez-Sanchez C, Montoya
J, Wallace DC, Lopez-Perez MJ (2006) Differences of sperm motility in
mitochondrial DNA haplogroup U sublineages. Gene 368, 21–27.
Niemi AK, Hervonen A, Hurme M, Karhunen PJ, Jylh€a M, Majamaa K (2003)
Mitochondrial DNA polymorphisms associated with longevity in a Finnish
population. Hum. Genet. 112, 29–33.
van Oven M, Kayser M (2009) Updated comprehensive phylogenetic tree of global
human mitochondrial DNA variation. Hum. Mutat. 30, E386–E394.
Passarino G, Rose G, Bellizzi D (2010) Mitochondrial function, mitochondrial DNA
and ageing: a reappraisal. Biogerontology 11, 575–588.
Pinos T, Nogales-Gadea G, Ruiz JR, Rodrıguez-Romo G, Santiago-Dorrego C,
Fiuza-Luces C, Gomez-Gallego F, Cano-Nieto A, Garatachea N, Moran M, Angel
Martın M, Arenas J, Andreu AL, Lucia A (2012) Are mitochondrial haplogroups
associatedwith extreme longevity? A study on aSpanish cohort.Age34, 227–233.
Rollins B, Martin MV, Sequeira PA, Moon EA, Morgan LZ, Watson SJ, Schatzberg
A, Akil H, Myers RM, Jones EG, Wallace DC, Bunney WE, Vawter MP (2009)
Mitochondrial variants in schizophrenia, bipolar disorder, and major depressive
disorder. PLoS ONE 4, e4913.
Rose G, Passarino G, Carrieri G, Altomare K, Greco V, Bertolini S, Bonafe M,
Franceschi C, De Benedictis G (2001) Paradoxes in longevity: sequence analysis
of mtDNA haplogroup J in centenarians. Eur. J. Hum. Genet. 9, 701–707.
Rose G, Passarino G, Franceschi C, De Benedictis G (2002) The variability of the
mitochondrial genome in human aging: a key for life and death? Int. J. Biochem.
Cell Biol. 34, 1449–1460.
Ross OA, McCormack R, Curran MD, Duguid RA, Barnett YA, Rea IM, Middleton D
(2001) Mitochondrial DNA polymorphism: its role in longevity of the Irish
population. Exp. Gerontol. 36, 1161–1178.
Ruiz-Pesini E, Lape~na AC, Dıez-Sanchez C, Perez-Martos A, Montoya J, Alvarez E,
Dıaz M, Urries A, Montoro L, Lopez-Perez MJ, Enrıquez JA (2000) Human
mtDNA haplogroups associated with high or reduced spermatozoa motility. Am.
J. Hum. Genet. 67, 682–696.
Santoro A, Salvioli S, Raule N, Capri M, Sevini F, Valensin S, Monti D, Bellizzi D,
Passarino G, Rose G, De Benedictis G, Franceschi C (2006) Mitochondrial DNA
involvement in human longevity. Biochim. Biophys. Acta 1757, 1388–1399.
Santoro A, Balbi V, Balducci E, Pirazzini C, Rosini F, Tavano F, Achilli A, Siviero P,
Minicuci N, Bellavista E, Mishto M, Salvioli S, Marchegiani F, Cardelli M, Olivieri F,
Nacmias B, Chiamenti AM, Benussi L, Ghidoni R, Rose G, Gabelli C, Binetti G,
Sorbi S, Crepaldi G, Passarino G, Torroni A, Franceschi C (2010) Evidence for
sub-haplogroup h5 of mitochondrial DNA as a risk factor for late onset
Alzheimer’s disease. PLoS ONE 5, e12037.
Shoffner JM, Brown MD, Torroni A, Lott MT, Cabell MF, Mirra SS, Beal MF, Yang
CC, Gearing M, Salvo R, Watts RL, Juncos JL, Hansen LA, Crain BJ, Fayad M,
Reckord CL, Wallace DC (1993) Mitochondrial DNA variants observed in
Alzheimer disease and Parkinson disease patients. Genomics 17, 171–184.
Skytthe A, Valensin S, Jeune B, Cevenini E, Balard F, Beekman M, Bezrukov V,
Blanche H, Bolund L, Broczek K, Carru C, Christensen K, Christiansen L,
Collerton JC, Cotichini R, de Craen AJ, Dato S, Davies K, De Benedictis G, Deiana
L, Flachsbart F, Gampe J, Gilbault C, Gonos ES, Haimes E, Hervonen A, Hurme
MA, Janiszewska D, Jylh€a M, Kirkwood TB, Kristensen P, Laiho P, Leon A,
Marchisio A, Masciulli R, Nebel A, Passarino G, Pelicci G, Peltonen L, Perola M,
Poulain M, Rea IM, Remacle J, Robine JM, Schreiber S, Scurti M, Sevini F, Sikora
E, Skouteri A, Slagboom PE, Spazzafumo L, Stazi MA, Toccaceli V, Toussaint O,
T€ornwall O, Vaupel JW, Voutetakis K, Franceschi C, GEHA consortium, (2011)
Design, recruitment, logistics, and data management of the GEHA (Genetics of
Healthy Ageing) project. Exp. Gerontol. 46, 934–945.
Suissa S, Wang Z, Poole J, Wittkopp S, Feder J, Shutt TE, Wallace DC, Shadel GS,
Mishmar D (2009) Ancient mtDNA genetic variants modulate mtDNA transcrip-
tion and replication. PLoS Genet. 5, e1000474.
Tanaka M, Gong JS, Zhang J, Yoneda M, Yagi K (1998) Mitochondrial genotype
associated with longevity. Lancet 351, 185–186.
Tanaka M, Gong J, Zhang J, Yamada Y, Borgeld HJ, Yagi K (2000) Mitochondrial
genotype associated with longevity and its inhibitory effect on mutagenesis.
Mech. Ageing Dev. 116, 65–76.
Torroni A, Huoponen K, Francalacci P, Petrozzi M, Morelli L, Scozzari R, Obinu D,
Savontaus ML, Wallace DC (1996) Classification of European mtDNAs from an
analysis of three European populations. Genetics 144, 1835–1850.
Torroni A, Petrozzi M, D’Urbano L, Sellitto D, ZevianiM, Carrara F, Carducci C, Leuzzi
V, Carelli V, Barboni P, De Negri A, Scozzari R (1997) Haplotype and phylogenetic
analyses suggest that one European-specific mtDNA background plays a role in
the expression of Leber hereditary optic neuropathy by increasing the penetrance
of the primary mutations 11778 and 14484. Am. J. Hum. Genet. 60, 1107–1121.
Vianello D, Sevini F, Castellani G, Lomartire L, Capri M, Franceschi C (2013)
HAPLOFIND: a New Method for High-Throughput mtDNA Haplogroup Assign-
ment. Hum. Mutat. 34, 1189–1194.
Wallace DC (2005) A mitochondrial paradigm of metabolic and degenerative
diseases, aging, and cancer: a dawn for evolutionary medicine. Annu. Rev.
Genet. 39, 359–407.
Wallace DC (2010) Mitochondrial DNA mutations in disease and aging. Environ.
Mol. Mutagen. 51, 440–450.
van der Walt JM, Nicodemus KK, Martin ER, Scott WK, Nance MA, Watts RL,
Hubble JP, Haines JL, Koller WC, Lyons K, Pahwa R, Stern MB, Colcher A, Hiner
BC, Jankovic J, Ondo WG, Allen FH Jr, Goetz CG, Small GW, Mastaglia F, Stajich
JM, McLaurin AC, Middleton LT, Scott BL, Schmechel DE, Pericak-Vance MA,
Vance JM (2003) Mitochondrial polymorphisms significantly reduce the risk of
Parkinson disease. Am. J. Hum. Genet. 72, 804–811.
Wang J, Wang W, Li R, Li Y, Tian G, Goodman L, Fan W, Zhang J, Li J, Zhang J, Guo
Y, Feng B, Li H, Lu Y, Fang X, Liang H, Du Z, Li D, Zhao Y, Hu Y, Yang Z, Zheng H,
Hellmann I, Inouye M, Pool J, Yi X, Zhao J, Duan J, Zhou Y, Qin J, Ma L, Li G,
Yang Z, Zhang G, Yang B, Yu C, Liang F, Li W, Li S, Li D, Ni P, Ruan J, Li Q, Zhu H,
Liu D, Lu Z, Li N, Guo G, Zhang J, Ye J, Fang L, Hao Q, Chen Q, Liang Y, Su Y,
San A, Ping C, Yang S, Chen F, Li L, Zhou K, Zheng H, Ren Y, Yang L, Gao Y,
Yang G, Li Z, Feng X, Kristiansen K, Wong GK, Nielsen R, Durbin R, Bolund L,
Zhang X, Li S, Yang H, Wang J (2008) The diploid genome sequence of an Asian
individual. Nature 456, 60–65.
Wu MC, Lee S, Cai T, Li Y, Boehnke M, Lin X (2011) Rare-variant association testing
for sequencing data with the sequence kernel association test. Am. J. Hum.
Genet. 89, 82–93.
Zheng X, Levine D, Shen J, Gogarten SM, Laurie C, Weir BS (2012) A
high-performance computing toolset for relatedness and principal component
analysis of SNP data. Bioinformatics 28, 3326–3328.
Supporting Information
Additional Supporting Information may be found in the online version of this
article at the publisher’s web-site.
Fig. S1 Scatterplot of the first two principal component scores based on the
229 SNPs (MAF > 0.01) identified in the 1291 mtDNA analyzed sequences.
Table S1. a and b. Haplogroup distribution in males and females.
Table S2. List of all the mutations identified in our sample by the complete
mtDNA sequencing.
Table S3. mtDNA mutations found in our study and previously associated
with diseases.
Table S4. Distribution of 90+ and controls from different centers participating
in the GEHA project.
Table S5. Sample distribution and general characteristics of the study
participants.
Table S6. Modified primer pairs for complete resequencing.
mtDNA variability and longevity, N. Raule et al. 407
ª 2013 The Authors. Aging Cell published by the Anatomical Society and John Wiley & Sons Ltd.
